Despite these limitations, our real-world study supports the available evidence provided by randomized trials and other real-world cohorts of the efficacy of first line pembrolizumab in patients with advanced high PD-L1 NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.